We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

1st Circ. To Size Up Antitrust Shield In Enoxaparin Row

Law360, Fort Wayne (February 8, 2017, 3:42 PM EST) -- The First Circuit on Thursday will consider whether a lower court correctly held that drugmaker Momenta was immune from a suit from rival Amphastar over a generic anticoagulant in a case that could redefine the limits of a decades-old doctrine shielding free speech from antitrust claims.

Amphastar Pharmaceuticals Inc. has asked the appeals court to overturn a Massachusetts federal judge’s determination that the Noerr-Pennington doctrine protected Momenta Pharmaceuticals Inc. and Sandoz Inc. from allegations that they conspired to keep Amphastar from selling enoxaparin.

The lower court...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.